107. Juvenile idiopathic arthritis Clinical trials / Disease details
Clinical trials : 441 / Drugs : 282 - (DrugBank : 56) / Drug target genes : 52 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00688545 (ClinicalTrials.gov) | April 2009 | 29/5/2008 | Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis | SINCERE™: Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry A Prospective Observational Registry Of Patients With Juvenile Idiopathic Arthritis (JIA) Treated With NSAIDs | Arthritis, Juvenile Rheumatoid | Drug: Celecoxib;Drug: nsNSAIDs | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | NULL | Terminated | 2 Years | 17 Years | All | 275 | United States |